SNS01-T: Additional Phase Ib/IIa data

Data from 14 evaluable patients with relapsed or refractory MM, DLBCL or MCL in an open-label, dose-escalation, U.S. Phase Ib/IIa trial showed that the maximum tolerated dose (MTD) of twice-weekly IV ...